(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 July 2014 (24.07.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/113357 A1

(51) **International Patent Classification**:
A61K 31/155 (2006.01) *A61P 3/10* (2006.01)
A61K 31/5383 (2006.01)

(21) **International Application Number**:
PCT/US2014/011394

(22) **International Filing Date**:
14 January 2014 (14.01.2014)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/753,567 17 January 2013 (17.01.2013) US

(71) **Applicant**: **TRANSTECH PHARMA, LLC** [US/US]; 4170 Mendenhall Oaks Parkway, High Point, North Carolina 27265 (US).

(72) **Inventors**: **MJALLI, Adnan M.M.**; 6421 Ashton Park Drive, Oak Ridge, North Carolina 27310 (US). **CLARK, Bradley Alan**; 3925 Pallas Way, Apt 1G, High Point, North Carolina 27265 (US). **POLISETTI, Dharma Rao**; 3741 Deerfield Street, High Point, North Carolina 27265 (US). **QUADA, JR., James C.**; 3605 Nina Court, High Point, North Carolina 27265 (US). **VALCARCE LOPEZ, Maria Carmen**; 1785 Deer Run Court, Oak Ridge, North Carolina 27310 (US). **ANDREWS, Robert Carl**; 3312 Morris Farm Drive, Jamestown, North Carolina 27282 (US). **DAVIS, Stephen Thomas**; 1 Wateroaks Court, Durham, North Carolina 27703 (US). **YOKUM, Thomas Scott**; 5108 Hartridge Way, Greensboro, North Carolina 27407 (US).

(74) **Agent**: **ROLLINS, Samuel B.**; 4170 Mendenhall Oaks Parkway, High Point, North Carolina 27265 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2014/113357 A1

(54) **Title**: COMBINATIONS OF A GLP1R AGONIST AND METFORMIN AND USE THEREOF FOR THE TREATMENT OF TYPE 2 DIABETES AND OTHER DISORDERS

(57) **Abstract**: The present invention provides uses of a glucagon-like peptide 1 receptor agonist in combination with metformin. Uses include treating type 2 diabetes, lowering blood glucose, and improving the therapeutic effectiveness of metformin. The invention also provides pharmaceutical compositions that comprise a GLP1R agonist and metformin.